COR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cencora is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act now and not wait for a better entry. The business fundamentals remain solid and Q2 earnings were strong on profitability, but the recent price action, bearish technical setup, and mixed Wall Street reaction after the revenue miss make this more of a hold than an immediate buy. If you already own it, keep it; if you do not, I would not initiate a full position at this moment.
COR is in a weak short-term technical position despite being oversold. MACD is negative and expanding, which confirms downside momentum. The RSI_6 at 11.984 shows the stock is deeply oversold, but the moving averages are still bearish with SMA_200 > SMA_20 > SMA_5, meaning the trend has not reversed yet. Price at 259.24 is just above S1 support at 258.92 and near S2 at 242.666, while still well below pivot resistance at 285.228. This suggests the stock may be near a short-term floor, but the trend is still not healthy enough to call it a clean buy.
["Q2 adjusted EPS grew 7.5% to $4.75 and full-year EPS guidance was raised to $17.65-$17.90.", "Revenue increased 3.85% year over year in the latest quarter.", "Net income surged 128.64% year over year, showing strong profitability improvement.", "Cencora announced a quarterly dividend of $0.60 and a $1.1 billion acquisition of EyeSouth Partners' retina business, which may support longer-term growth.", "Hedge funds have been aggressively buying, with buying amount up 2472.49% over the last quarter.", "Congress trading is balanced rather than negative, with 2 buys and 2 sells.", "Historical pattern data suggests a favorable short-term rebound probability after the recent selloff."]
["The latest quarter missed Wall Street revenue expectations, and the stock fell to a 52-week low after the report.", "Analysts have been cutting price targets across multiple firms, including Baird, Evercore ISI, and Citi.", "Technical trend remains bearish with negative MACD and bearish moving averages.", "Insiders are neutral with no significant buying signal.", "The stock is trading near support after a sharp decline, so the setup is still fragile for a new buyer."]
Latest quarter: fiscal Q2 2026. Revenue rose to $78.36 billion, up 3.85% year over year. Net income increased to $1.64 billion, up 128.64% year over year. EPS rose to 8.4, up 128.26% year over year, and gross margin improved to 4.26, up 22.77% year over year. The key takeaway is that profitability improved strongly, but revenue growth was modest and below expectations.
Wall Street is still mostly positive, but sentiment has cooled. Baird, Evercore ISI, and Citi all cut price targets after the disappointing U.S. healthcare results and revenue miss, though they kept constructive ratings. UBS even raised its target to $412 and kept a Buy rating. William Blair initiated at Market Perform, noting favorable demand trends but preferring Cardinal Health. Overall, pros still see upside potential, but the recent pattern is clearly one of lower price targets and more caution.
